BioSpace News Archive

Mallinckrodt today confirmed enrollment of the first patient in the company’s Phase 4, multi-center, randomized, double-blind, placebo-controlled pilot study to further assess the efficacy of H.P. Acthar Gel as a therapy option in patients with pulmonary sarcoidosis.

Sales in the first nine months of FY2017 decreased 0.6% compared to those in the corresponding period of the previous fiscal year (“year-on-year”) to ¥999.4 billion due to the impact of certain items such as the transfer of the global dermatology business in April 2016 and the transfer of long-listed products in Japan in April 2017.

Avita Medical announced that it filed today with the ASX its Appendix 4C - Quarterly Cash Flow Report for the quarter ended 31 December 2017.

The Phase 2b clinical trial will test two concentrations of topical reproxalap against vehicle over 12 weeks of treatment in 300 patients with moderate dry eye disease.

Shire’s decision was based on a study that compared their existing CLD workflow to a workflow using the Beacon.

Bioasis today announced that it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended Nov. 30, 2017.

The study showed that patients who underwent the MP-TKA scored significantly better on the Forgotten Joint Score (FJS) than those who underwent the PS-TKA, particularly with regard to deep knee flexion and stability of the prosthesis.

Birst today announced that DJO Global, a leading global provider of medical devices for rehabilitation, pain management and physical therapy, is using the Birst cloud analytics platform to boost business agility and productivity.

The ENDEAVOR trial demonstrated that Kd reduced the risk of death by 21 percent and increased OS by 7.6 months versus Vd in patients with relapsed or refractory multiple myeloma.

The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer.